These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 19877243)

  • 1. When does Parkinson's disease begin?
    Gaig C; Tolosa E
    Mov Disord; 2009; 24 Suppl 2():S656-64. PubMed ID: 19877243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can we image premotor Parkinson disease?
    Marek K; Jennings D
    Neurology; 2009 Feb; 72(7 Suppl):S21-6. PubMed ID: 19221310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-motor extranigral signs and symptoms in Parkinson's disease.
    Wolters ECh
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S6-12. PubMed ID: 20083010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Non-motor disorders in Parkinson's disease].
    Merello M
    Rev Neurol; 2008 Sep 1-15; 47(5):261-70. PubMed ID: 18780273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When does Parkinson's disease begin? From prodromal disease to motor signs.
    Meissner WG
    Rev Neurol (Paris); 2012 Nov; 168(11):809-14. PubMed ID: 22981298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A timeline for Parkinson's disease.
    Hawkes CH; Del Tredici K; Braak H
    Parkinsonism Relat Disord; 2010 Feb; 16(2):79-84. PubMed ID: 19846332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression.
    Marek K; Jennings D; Tamagnan G; Seibyl J
    Ann Neurol; 2008 Dec; 64 Suppl 2():S111-21. PubMed ID: 19127587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease.
    Banati RB; Daniel SE; Blunt SB
    Mov Disord; 1998 Mar; 13(2):221-7. PubMed ID: 9539333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's disease: clinical aspects.
    Klockgether T
    Cell Tissue Res; 2004 Oct; 318(1):115-20. PubMed ID: 15365814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.
    Prediger RD
    J Alzheimers Dis; 2010; 20 Suppl 1():S205-20. PubMed ID: 20182024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical criteria for the diagnosis of Parkinson's disease.
    Reichmann H
    Neurodegener Dis; 2010; 7(5):284-90. PubMed ID: 20616563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of nigral cell death in Parkinson's disease.
    Przedborski S
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S3-7. PubMed ID: 15885625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
    Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
    Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical measures of progression in Parkinson's disease.
    Poewe W
    Mov Disord; 2009; 24 Suppl 2():S671-6. PubMed ID: 19877235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's at risk syndrome: can Parkinson's disease be predicted?
    Stern MB; Siderowf A
    Mov Disord; 2010; 25 Suppl 1():S89-93. PubMed ID: 20187248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's disease risk score: moving to a premotor diagnosis.
    Winkler J; Ehret R; Büttner T; Dillmann U; Fogel W; Sabolek M; Winkelmann J; Kassubek J
    J Neurol; 2011 May; 258(Suppl 2):S311-5. PubMed ID: 21560061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological changes in dendrites of substantia nigra neurons in Parkinson's disease: a Golgi study.
    Patt S; Gertz HJ; Gerhard L; Cervós-Navarro J
    Histol Histopathol; 1991 Jul; 6(3):373-80. PubMed ID: 1725760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.